ASNDAscendis Pharma A/S
$243.19+17% 1Y
$243.19
$196.0152 weeks$276.87
Is the business good?
Good
1 good, 3 without dataMargins widening. That is the only one of 4 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Margin direction, 3 years+1409.9 ptsderived
Operating margin has widened over the past few years, the business is getting more profitable per dollar of sales.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is ASND?
Ascendis Pharma A/S keeps −19% of every revenue dollar as operating profit, against −82% for the median Biotechnology name.
−19%
Operating margin · Biotechnology median −82% · 12 months to Q4 2025
- R&D as % of revenue
- 42%
R&D as % of revenue
- Gross margin
- 87%
Gross margin
| Year | Operating margin |
|---|---|
| FY2020 | −4755% |
| FY2021 | −5809% |
| FY2022 | −1098% |
| FY2023 | −171% |
| FY2024 | −77% |
| FY2025 | −19% |
Details›
- Gross margin12 months to Q4 2025
- 87%
- Operating margin12 months to Q4 2025
- −19%
- Net margin12 months to Q4 2025
- −32%
- R&D as % of revenue
- 42%
- Revenue, trailing twelve months
- $720M
- Net income, trailing twelve months
- −$228M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.